Pneumococcal conjugate vaccines for preventing otitis media

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 4, 2014, Pages

  Fortanier, Alexandre C ^a   Venekamp, Roderick P ^a   Boonacker, Chantal W B ^a   Hak, Eelko ^b   Schilder, Anne G M ^c   Sanders, Elisabeth A M ^d   Damoiseaux, Roger A M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GSK 1024850 A; PNEUMOCOCCUS VACCINE; VACCINE;

ACUTE OTITIS MEDIA; DISEASE SEVERITY; DRUG EFFECT; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; VACCINATION; ACUTE DISEASE; CHILD; INFANT; MICROBIOLOGY; OTITIS MEDIA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE DISEASE; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; OTITIS MEDIA; PNEUMOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, CONJUGATE;

EID: 84928395883     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001480.pub4     Document Type: Review

References (85)

1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al.Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatric Infectious Disease Journal 2000;19(3):187-95.
2. Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatric Infectious Disease Journal 2001;20(10):951-8.
3. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al.Efficacy of a pneumococcal conjugate vaccine against acute otitis media. New England Journal of Medicine 2001;344(6):403-9.
4. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatric Infectious Disease Journal 2003;22:10-6.
5. Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled trial. Journal of Pediatrics 2008;153:764-70.
6. Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, et al.Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clinical Infectious Diseases 2003;37(9):1155-64.
7. O'Brien KL, David AB, Chandran A, Moulton LH, Reid R, Weatherholtz R, et al.Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatric Infectious Disease Journal 2008;27:71-3.
8. Palmu AA, Saukkoriipi A, Jokinen J, Leinonen M, Kilpi TM. Efficacy of pneumococcal conjugate vaccine against PCR-positive acute otitis media. Vaccine 2009;27:1490-1.
9. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al.Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367(9512):740-8.
10. Van Kempen MJ, Vermeiren JS, Vaneechoutte M, Claeys G, Veenhoven RH, Rijkers GT, et al.Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?. International Journal of Pediatric Otorhinolaryngology 2006;70(2):275-85.
11. Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J, et al.Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 2003;361(9376):2189-95.
12. Gisselsson-Solén M, Melhus A, Hermansson A. Pneumococcal vaccination in children at risk of developing recurrent acute otitis media - a randomized study. Acta Paediatrica 2011;100:1354-8.
13. Jokinen J, Palmu AA, Kilpi T. Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clinical Infectious Diseases 2012;55:1673-6.
14. Le TM, Rovers MM, Veenhoven RH, Sanders EA, Schilder AG. Effect of pneumococcal vaccination on otitis media with effusion in children older than 1 year. European Journal of Pediatrics 2007;166:1049-52.
15. Roy E, Steinhoff MC, Omer SB, Arifeen SE, Raqib R, Breiman R, et al.Clinical effectiveness of pneumococcal conjugate vaccine in suppurative otitis media: a randomized controlled trial in Bangladeshi Infants. Pediatric Academic Societies Annual Meeting (April 28 - May 1). Boston, USA, 2011.
16. NCT00466947. COMPAS: Phase III, Double-blind, Randomized Study to Demonstrate Efficacy of GSK Biologicals' Pneumococcal Conjugate Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media (AOM). clinicaltrials.gov/show/NCT00466947 (accessed 1 December 2013).
17. NCT00861380. Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (FinIP). clinicaltrials.gov/show/NCT00861380 (accessed 1 December 2013).
18. NCT01174849. Pneumococcal Vaccines Early and in Combination (PREVIX_COMBO). clinicaltrials.gov/show/NCT01174849 (accessed 1 December 2013).
19. NCT01545375. Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children. clinicaltrials.gov/show/NCT01545375 (accessed 1 December 2013).
20. NCT01735084. Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life (PREV-IX_B). clinicaltrials.gov/show/NCT01735084 (accessed 1 December 2013).
21. Alonso M, Marimon JM, Ercibengoa M, Pérez-Yarza EG, Pérez-Trallero E. Dynamics of Streptococcus pneumoniae serotypes causing acute otitis media isolated from children with spontaneous middle-ear drainage over a 12-year period (1999-2010) in a region of northern Spain. PLoS ONE 2013;8(1):e54333.
22. Andersen PK, Gill RD. Cox regression model for counting processes: a large sample study. Annals of Statistics 1982;10(4):1100-20.
23. Arason VA, Kristinsson KG, Sigurdsson JA, Stefánsdóttir G, Mölstad S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ 1996;313(7054):387-91.
24. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, et al.Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatric Infectious Disease Journal 2004;23(9):829-33.
25. Block SL. Searching for the Holy Grail of acute otitis media. Archives of Diseases in Childhood 2006;91(12):959-61.
26. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatric Infectious Disease Journal 1992;11(8 Suppl):7-11.
27. Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review. Pharmacoeconomics 2011;29(3):199-211.
28. Casey JR, Pichichero ME. Changes in the frequency and pathogens causing acute otitis media in 1995-2003. Pediatric Infectious Disease Journal 2004;9:824-8.
29. Casey JR, Kaur R, Friedel VC, Pichichero ME. Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York. Pediatric Infectious Disease Journal 2013;32:805-9.
30. Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ, Shekelle PG, et al.Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010;304:2161-9.
31. Couloigner V, Levy C, François M, Bidet P, Cohen R, et al.Pathogens implicated in acute otitis media failures after 7-valent pneumococcal conjugate vaccine implementation in France: distribution, serotypes, and resistance levels. Pediatric Infectious Disease Journal 2012;31(2):154-8.
32. Dagan R, Melamed R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatric Infectious Disease Journal 1997;16(11):1053-9.
33. Dagan R. Treatment of acute otitis media - challenges in the era of antibiotic resistance. Vaccine 2000;19(Suppl 1):9-16.
34. Dagan R, Leibovitz E, Greenberg D, Bakaletz L, Givon-Lavi N. Mixed pneumococcal-nontypeable Haemophilus influenzae otitis media is a distinct clinical entity with unique epidemiologic characteristics and pneumococcal serotype distribution. Journal of Infectious Diseases 2013;208(7):1152-60.
35. del Castillo F, Baquero-Artigao F, Garcia-Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain. Pediatric Infectious Disease Journal 1998;17(2):94-7.
36. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatric Infectious Disease Journal 1999;18(6):543-51.
37. Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clinical Infectious Diseases 2008;46(5):726-31.
38. Goossens H, Ferech M, Coenen S, Stephens P. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clinical Infectious Diseases 2007;44(8):1091-5.
39. Hausdorff W, Mrkvan T, Moreira M, Ruiz Guinazu J, Borys D. Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on pneumococcal disease. Proceedings of the 28th International Congress of Chemotherapy and Infection Incorporating the 14th Asia-Pacific Congress of Clinical Microbiology and Infection; 2013 June 5-8; Yokohama, Japan. International Journal of Antimicrobial Agents 2013;42 Suppl 2:S157.
40. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. New England Journal of Medicine 1999;340(4):260-4.
41. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
42. Howie VM, Ploussard JH, Lester RL Jr. Otitis media: a clinical and bacteriological correlation. Pediatrics 1970;45(1):29-35.
43. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrobial Agents and Chemotherapy 1998;42(3):589-95.
44. Jahn-Eimermacher A, du Prel JB, Schmitt HJ. Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical practice in randomized controlled clinical trials. Vaccine 2007;25(33):6237-44.
45. Kaplan B, Wandstrat TL, Cunningham JR. Overall cost in the treatment of otitis media. Pediatric Infectious Disease Journal 1997;16(2 Suppl):9-11.
46. Kaur R, Casey JR, Pichichero ME. Relationship with original pathogen in recurrence of acute otitis media after completion of amoxicillin/clavulanate: bacterial relapse or new pathogen. Pediatric Infectious Disease Journal 2013;32(11):1159-62.
47. Kvaerner KJ, Nafstad P, Hagen JA, Mair IW, Jaakkola JJ. Recurrent acute otitis media: the significance of age at onset. Acta Oto-Laryngologica 1997;117(4):578-84.
48. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org. Chichester, UK: Wiley-Blackwell, 2011.
49. Luotonen J, Herva E, Karma P, Timonen M, Leinonen M, Makela PH. The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods. Scandinavian Journal of Infectious Diseases 1981;13(3):177-83.
50. Magnus MC, Vestrheim DF, Nystad W, Håberg SE, Stigum H. Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination. Pediatric Infectious Disease Journal 2012;31(9):951-5.
51. Marom T, Tan A, Wilkinson GS, Pierson KS, Freeman JL, Chonmaitree T. Trends in otitis media-related health care use in the United States, 2001-2011. JAMA Pediatrics 2014;168(1):68-75.
52. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman and Hall, 1989.
53. McEllistrem MC, Adams JM, Patel K, Medelsohn AB, Kaplan SL, Bradley JS, et al.Acute otitis media due to penicillin-non-susceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clinical Infectious Diseases 2005;40:1738-44.
54. Moulton LH, O'Brien KL, Kohberger R, Chang I, Reid R, Weatherholtz R, et al.Design of a group-randomized Streptococcus pneumoniae vaccine trial. Controlled Clinical Trials 2001;22:438-52.
55. Niemela M, Uhari M, Mottonen M, Pokka T. Costs arising from otitis media. Acta Paediatrica 1999;88(5):553-6.
56. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al.Efficacy and safety of a seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 2003;362(9381):255-61.
57. O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M. New vaccines against otitis media: projected benefits and cost-effectiveness. Pediatrics 2009;123:1452-63.
58. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996;348(9022):271-2.
59. Palmu A, Jokinen J, Kilpi T, Finnish Otitis Media Study Group. Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine. Vaccine 2008;26(20):2466-70.
60. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, et al.Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013;381(9862):214-22.
61. Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, et al.Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infectious Diseases 2013;14(3):205-12. [DOI: 10.1016/S1473-3099(13)70338-4].
62. Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009;123(6):e1103-10.
63. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007;298:1772-8.
64. Pichichero ME, Casey JR, Almudevar A. Nonprotective responses to pediatric vaccines occur in children who are otitis prone. Pediatric Infectious Disease Journal 2013;32(11):1163-8.
65. Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, et al.Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007;119(4):707-15.
66. Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, et al.Antibiotics for acute otitis media: a meta-analysis with individual patient data. Lancet 2006;368(9545):1429-35.
67. Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, et al.Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatric Infectious Disease Journal 1999;18(9):757-63.
68. Somech I, Dagan R, Givon-Lavi N, Porat N, Raiz S, Leiberman A, et al.Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine. Vaccine 2011;29:4202-9.
69. Sox CM, Finkelstein JA, Yin R, Kleinman K, Lieu TA. Trends in otitis media treatment failure and relapse. Pediatrics 2008;121:674-9.
70. Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, Bogaert D, et al.Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PloS One 2012;7(6):e39730.
71. Spiro DM, Arnold DH. The concept and practice of a wait-and-see approach to acute otitis media. Current Opinion in Pediatrics 2008;20(1):72-8.
72. Taylor S, Marchisio P, Vergison A, Harriague J, Hausdorff WP, Haggard M. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clinical Infectious Diseases 2012;54(12):1765-73.
73. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. Journal Infectious Disease 1989;160:83-94.
74. van den Bergh MR, Biesbroek G, Rossen JW, de Steenhuijsen Piters WA, Bosch AA, van Gils EJ, et al.Associations between pathogens in the upper respiratory tract of young children: interplay between viruses and bacteria. PloS One 2012;7(10):e47711.
75. van den Bergh MR, Spijkerman J, Swinnen KM, François NA, Pascal TG, Borys D, et al.Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clinical Infectious Diseases 2013;56(3):e30-9.
76. Veenhoven RH, Bogaert D, Schilder AG, Rijkers GT, Uiterwaal CS, Kiezebrink HH, et al.Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clinical Infectious Diseases 2004;39(7):911-9.
77. Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers MM. Antibiotics for acute otitis media in children. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD000219.pub3].
78. World Health Organization. Pneumococcal vaccines WHO position paper - 2012 - Recommendations. Vaccine 2012;30(32):4717-8.
79. Wiertsema SP, Kirkham LA, Corscadden KJ, Mowe EN, Bowman JM, Jacoby P, et al.Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule. Vaccine 2011;29(32):5163-70.
80. Wiertsema SP, Corscadden KJ, Mowe EN, Zhang G, Vijayasekaran S, Coates HL, et al.IgG responses to pneumococcal and Haemophilus influenzae protein antigens are not impaired in children with a history of recurrent acute otitis media. PLoS One 2012;7(11):e49061.
81. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008;121:253-60.
82. Jansen AG, Hak E, Veenhoven RH, Damoiseaux RA, Schilder AG, Sanders EA. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD001480.pub3].
83. Straetemans M, Sanders EA, Veenhoven RH, Schilder AG, Damoiseaux RA, Zielhuis GA. Pneumococcal vaccines for preventing otitis media. Cochrane Database of Systematic Reviews 2002, Issue 2. Art, No.: CD001480. [DOI: 10.1002/14651858.CD001480].
84. Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA. Review of randomized controlled trials on pneumococcal vaccination for prevention of otitis media. Pediatric Infectious Disease Journal 2003;22(6):515-24.
85. Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA. Pneumococcal vaccines for preventing otitis media. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD001480.pub2].